- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about TAK
Recent news which mentions TAK
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
November 23, 2022
From Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
November 22, 2022
From Benzinga
Why Puma Biotechnology's Shares Jumped 20% on Monday
November 21, 2022
From Motley Fool
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
November 17, 2022
From Benzinga
From Motley Fool
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
November 02, 2022
From Motley Fool
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
October 27, 2022
From Benzinga
Earnings Scheduled For October 27, 2022
October 27, 2022
From Benzinga
7 Dividend Stocks to Sell Pronto Before a Painful Downturn
October 24, 2022
From InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
October 19, 2022
From Benzinga
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
October 19, 2022
From Motley Fool
From Benzinga
3 IPO Stocks That You Want to Own
September 25, 2022
From Motley Fool
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
September 21, 2022
From Benzinga
Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years
September 14, 2022
From Motley Fool
7 Stocks Under $15 to Buy and Hold Forever
September 01, 2022
From InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 30, 2022
From Benzinga
From Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
August 30, 2022
From Benzinga
From Benzinga
From Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 22, 2022
From Benzinga
Peering Into Takeda Pharmaceutical's Recent Short Interest
August 08, 2022
Tickers
TAK
From Benzinga
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
July 27, 2022
From Benzinga
Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents
July 26, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
What's Winning in 2022? 3 Stocks That Are Doing Fine
July 16, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.